Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trivax
- Development stage
- Phase 2
- Lead developer
- AOP Health
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intranodal
01
Overview
Trivax is an anti-tumor immune therapy developed by Activartis Biotech. It is based on tumor-lysate charged dendritic cells, designed to stimulate the patient's immune system to recognize and attack cancer cells. It is currently being investigated as an add-on treatment for Glioblastoma Multiforme, in combination with standard therapy including Temozolomide and radiotherapy.
Beyond the preview
Go deeper on Trivax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trivax.